$SNPX
Synaptogenix, Inc. Stock $snpx

$snpx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000410 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.082M	$1.555M	$6.339M
YoY Change	-47.06%	-65.27%	-35.38%
% of Gross Profit
Research & Development	$609.2K	$577.9K	$1.975M
YoY Change	-30.59%	-59.1%	-68.78%
% of Gross Profit
Depreciation & Amortization	$1.399K	-$3.650K	$6.350K
YoY Change	-17.22%	-340.13%	11.13%
% of Gross Profit
Operating Expenses	$1.691M	$2.132M	$8.314M
YoY Change	-42.11%	-63.79%	-48.47%
Operating Profit
YoY Change
Interest Expense	$1.427M	$821.4K	$905.4K
YoY Change	17.9%	-92.08%	-91.43%
% of Operating Profit
Other Income/Expense, Net	$1.485M	$315.0K	$1.370M
YoY Change	22.69%	-96.25%	-87.03%
Pretax Income	-$206.7K	-$996.0K	-$6.039M
YoY Change	-87.92%	-122.22%	8.33%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$206.7K	-$1.229M	-$13.78M
YoY Change	-87.92%	-128.16%	147.21%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.41		-$1.18
Diluted Earnings Per Share	-$0.41	-$1.45	-$29.56
COMMON SHARES
Basic Shares Outstanding	27.13M	20.39M	11.65M
Diluted Shares Outstanding	1.037M		11.65M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.24M	$28.66M	$28.66M
YoY Change	-21.08%	-23.53%	-23.53%
Cash & Equivalents	$26.30M	$28.66M	$28.66M
Short-Term Investments	$1.938M	$1.439M
Other Short-Term Assets	$2.498M	$1.871M	$1.871M
YoY Change	243.98%	69.01%	69.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$28.83M	$30.53M	$30.53M
YoY Change	-21.03%	-20.87%	-20.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.11K	$18.51K	$18.51K
YoY Change	-23.95%	-16.41%	-16.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$553.8K	$562.4K	$562.4K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$570.9K	$580.9K	$580.9K
YoY Change	2438.16%	2523.21%	2522.62%
TOTAL ASSETS
Total Short-Term Assets	$28.83M	$30.53M	$30.53M
Total Long-Term Assets	$570.9K	$580.9K	$580.9K
Total Assets	$29.40M	$31.11M	$31.11M
YoY Change	-19.52%	-19.41%	-19.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$238.9K	$444.6K	$444.6K
YoY Change	-32.87%	-32.65%	-32.65%
Accrued Expenses	$45.69K	$3.832M	$3.832M
YoY Change	-91.52%	613.94%	613.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.300M	$4.276M	$4.276M
YoY Change	393.39%	225.75%	225.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$223.0K	$1.253M	$1.253M
YoY Change	-79.09%	-33.36%	-33.36%
Total Long-Term Liabilities	$223.0K	$1.253M	$1.253M
YoY Change	-79.09%	-33.36%	-33.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.300M	$4.276M	$4.276M
Total Long-Term Liabilities	$223.0K	$1.253M	$1.253M
Total Liabilities	$6.523M	$5.529M	$5.529M
YoY Change	178.35%	73.17%	73.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$34.04M	-$33.61M
YoY Change	56.06%	69.48%
Common Stock	$109.00	$2.411K
YoY Change	-85.21%	231.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.05M	$25.58M	$25.58M
YoY Change
Total Liabilities & Shareholders Equity	$29.40M	$31.11M	$31.11M
YoY Change	-19.52%	-19.41%	-19.41%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$206.7K	-$1.229M	-$13.78M
YoY Change	-87.92%	-128.16%	147.21%
Depreciation, Depletion And Amortization	$1.399K	-$3.650K	$6.350K
YoY Change	-17.22%	-340.13%	11.13%
Cash From Operating Activities	-$1.832M	-$1.063M	-$5.173M
YoY Change	8.0%	-61.8%	-53.86%
INVESTING ACTIVITIES
Capital Expenditures		$2.710K	$2.710K
YoY Change		27.23%	-63.45%
Acquisitions
YoY Change
Other Investing Activities	-$500.0K	-$2.000M	-$2.000M
YoY Change
Cash From Investing Activities	-$500.0K	-$2.003M	-$2.003M
YoY Change	24433.86%	93923.94%	26912.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$1.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-1.070K	-1.641M
YoY Change		-100.01%	-111.33%
NET CHANGE
Cash From Operating Activities	-1.832M	-1.063M	-5.173M
Cash From Investing Activities	-500.0K	-2.003M	-2.003M
Cash From Financing Activities		-1.070K	-1.641M
Net Change In Cash	-2.332M	-3.067M	-8.817M
YoY Change	37.32%	-127.52%	-370.09%
FREE CASH FLOW
Cash From Operating Activities	-$1.832M	-$1.063M	-$5.173M
Capital Expenditures		$2.710K	$2.710K
Free Cash Flow		-$1.066M	-$5.176M
YoY Change		-61.74%	-53.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001571934
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Registrant Name EntityRegistrantName	Synaptogenix, Inc.
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	15000
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24089646
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7267032
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-249434
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1585656
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2023	dei	City Area Code CityAreaCode	973
CY2023	dei	Local Phone Number LocalPhoneNumber	242-0005
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par valueper share
CY2023	dei	Trading Symbol TradingSymbol	SNPX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q4	snpx	Temporary Equity Liquidation Preference Percentage Of Accrued Dividends TemporaryEquityLiquidationPreferencePercentageOfAccruedDividends	0.07
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6623571
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27133349
CY2023	dei	Auditor Name AuditorName	Morison Cogen LLP
CY2023	dei	Auditor Location AuditorLocation	Blue Bell, PA
CY2023	dei	Auditor Firm AuditorFirmId	536
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28661498
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37478480
CY2023Q4	snpx	Prepaid Clinical Trial Expenses PrepaidClinicalTrialExpenses	375085
CY2022Q4	snpx	Prepaid Clinical Trial Expenses PrepaidClinicalTrialExpenses	367714
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1438500
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57677
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	739467
CY2023Q4	us-gaap	Assets Current AssetsCurrent	30532760
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38585661
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	562402
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18505
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22145
CY2023Q4	us-gaap	Assets Assets	31113667
CY2022Q4	us-gaap	Assets Assets	38607806
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	444633
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	660206
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	435891
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	536714
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	115890
CY2023Q4	snpx	Temporaray Equity Accrued Amount Payable Current TemporarayEquityAccruedAmountPayableCurrent	3395945
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4276469
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1312810
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	140000
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1510000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1113000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	370300
CY2023Q4	us-gaap	Liabilities Liabilities	5529469
CY2022Q4	us-gaap	Liabilities Liabilities	3193110
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022	snpx	Temporary Equity Face Value Per Share TemporaryEquityFaceValuePerShare	1000
CY2023	snpx	Temporary Equity Face Value Per Share TemporaryEquityFaceValuePerShare	1000
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	6000
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	15000
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	6000000
CY2023Q4	snpx	Temporary Equity Liquidation Preference Amount Of Accrued Dividends TemporaryEquityLiquidationPreferenceAmountOfAccruedDividends	140000
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1236940
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	2721723
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24089646
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7267032
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2411
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	728
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57954693
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52523762
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	902
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33610748
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19831517
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24347258
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32692973
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31113667
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38607806
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1974924
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6324928
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6338930
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9810068
CY2023	us-gaap	Operating Expenses OperatingExpenses	8313854
CY2022	us-gaap	Operating Expenses OperatingExpenses	16134996
CY2023	us-gaap	Interest Income Other InterestIncomeOther	1648950
CY2022	us-gaap	Interest Income Other InterestIncomeOther	335039
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1370000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8405000
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-743600
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1821000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2275350
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10561039
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6038504
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5573957
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6038504
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5573957
CY2023	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	2047774
CY2022	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	115890
CY2023	snpx	Deemed Dividend Related To Temporary Equity Extinguishment DeemedDividendRelatedToTemporaryEquityExtinguishment	5693000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13779278
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5689847
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	902
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13778376
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5689847
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.18
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11651900
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11651900
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6989200
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6989200
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33529748
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3743963
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	196603
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	359356
CY2022	snpx	Temporary Equity Stock Issued During Period Discount And Issuance Costs TemporaryEquityStockIssuedDuringPeriodDiscountAndIssuanceCosts	12278277
CY2022	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	115890
CY2022	snpx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	553150
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5573957
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32692973
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32692973
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1009325
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	118000
CY2023	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1022149
CY2023	snpx	Adjustment To Additional Paid In Capital Temporary Equity Extinguishment Of Deemed Dividend AdjustmentToAdditionalPaidInCapitalTemporaryEquityExtinguishmentOfDeemedDividend	-210207
CY2023	snpx	Temporary Equity Redemption Value TemporaryEquityRedemptionValue	-5163886
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	7366968
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	902
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6038504
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24347258
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6038504
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5573957
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1009325
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3743963
CY2022	snpx	Warrant Issuance Costs WarrantIssuanceCosts	898023
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1370000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8405000
CY2023	snpx	Fair Value Of Derivative Liability FairValueOfDerivativeLiability	-743600
CY2022	snpx	Fair Value Of Derivative Liability FairValueOfDerivativeLiability	1821000
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	118000
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	359356
CY2022	snpx	Issuance Of Stock And Warrants For Services IssuanceOfStockAndWarrantsForServices	196603
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6347
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5714
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-674419
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-183045
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-215573
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-636300
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-100823
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-161692
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	865295
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-5637288
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5173209
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11211245
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	562402
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1437598
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2707
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7414
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2002707
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7414
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	13930000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	553150
CY2023	snpx	Payments To Redemption Of Temporary Equity PaymentsToRedemptionOfTemporaryEquity	1000000
CY2023	snpx	Payments To Dividends Of Temporary Equity PaymentsToDividendsOfTemporaryEquity	641066
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1641066
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14483150
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8816982
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3264491
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37478480
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34213989
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28661498
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37478480
CY2023	us-gaap	Stock Issued1 StockIssued1	5979257
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	7366968
CY2023	snpx	Temporary Equity Modification Deemed Dividend TemporaryEquityModificationDeemedDividend	5693000
CY2023	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	3395945
CY2022	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	115890
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	902
CY2022	snpx	Initial Fair Value Of Warrant Liability Pursuant To Private Placement Of Preferred Stock And Warrants InitialFairValueOfWarrantLiabilityPursuantToPrivatePlacementOfPreferredStockAndWarrants	9915000
CY2022	snpx	Initialfairvalueofderivativeliabilitypursuant To Private Placement Of Preferred Stock And Warrants InitialfairvalueofderivativeliabilitypursuantToPrivatePlacementOfPreferredStockAndWarrants	2191300
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and the Company operates independently from Neurotrope. On December 7, 2020, the Company became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”) when the Company filed an amended and restated certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. The Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), are listed on The Nasdaq Capital Market under the symbol “SNPX.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neurotrope Bioscience, Inc. was incorporated in Delaware on October 31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). The Company is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”) in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 3 - Collaborative Agreements and Commitments).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the separation from Neurotrope, the Company entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties’ various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2022, the Company issued a press release announcing that an extended confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD (Study #204) did not achieve statistical significance on the primary endpoint, which was changed from baseline to Week 13 in the Severe Impairment Battery (“SIB”) total score assessment obtained after completion of the second seven-dose course of treatment (week 28 of trial). On March 7, 2023, the Company announced results of its analysis of secondary endpoints and post hoc analysis from our Phase 2 study of Bryostatin-1. In the secondary endpoint analysis, changes from baseline at Weeks 9, 20, 24, 30, and 42 in the SIB (Severe Impairment Battery) total score were not statistically significant in the total patient population, and no pre-specified secondary endpoints were met with statistical significance in the low-to-moderately severe AD patient stratum. However, nearly all pre-specified secondary endpoints in the most advanced and severe AD (Mini Mental State Exam 2 (“MMSE”) (baseline scores: 10-14) patient population, with baseline MMSE-2 (Mini-Mental State Examination, 2nd Edition) scores of 10-14, were achieved with statistical significance (p = <0.05, 2-tailed). Data also showed statistical significance in exploratory secondary endpoints for the MMSE-2 10-14 stratum, and post hoc analysis was positive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 24, 2023, the Company received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company received an initial grace period of 180 calendar days, or until October 23, 2023 (the “Initial Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. Compliance could be achieved automatically and without further action if the closing bid price of the Company’s stock remained at or above $1.00 for a minimum of 10 consecutive business days at any time during the Initial Compliance Period. On October 24, 2023, the Company received a second written notice from Nasdaq, notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the Initial Compliance Period and granting the Company an additional grace period of 180 calendar days, or until April 22, 2024 (the “Second Compliance Period”), to regain compliance. Compliance can be achieved automatically and without further action if the closing bid price of the Company’s stock remains at or above $1.00 for a minimum of 10 consecutive business days at any time during the Second Compliance Period, in which case Nasdaq will notify the Company of its compliance and the matter will be closed. If, however, the Company does not achieve compliance with the Minimum Bid Price Requirement during the Second Compliance Period, Nasdaq will notify the Company that its common stock will be delisted subject to an opportunity for the Company to appeal. As of the date of this Annual Report, the Company had not yet regained compliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Liquidity Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had approximately $28.7 million in cash and cash equivalents as compared to $37.5 million at December 31, 2022. The Company expects that its current cash and cash equivalents, approximately $26.3 million as of the date of this Annual Report, will be sufficient to support its projected operating requirements and financial commitments for at least the next 12 months from this date. The operating requirements include the current development plans for Bryostatin-1, our novel drug candidate targeting the activation of Protein Kinase C Epsilon and other development projects. The financial commitments include the potential redemption of the Series B Convertible Preferred Stock for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the ongoing Phase 2 trial of Bryostatin-1. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Other Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing, or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (“NCI”), pursuant to which the NCI has agreed to supply bryostatin required for the Company’s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (“FDA”) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company will have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize Bryostatin-1 for the treatment of AD. In June 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to be the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram of synthetic bryostatin. See Note 3.</p>
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	snpx	Number Of Preceding Consecutive Business Days Failure To Maintain Minimum Closing Bid Price NumberOfPrecedingConsecutiveBusinessDaysFailureToMaintainMinimumClosingBidPrice	30
CY2023Q2	snpx	Minimum Closing Bid Price Failed To Maintain In Preceding Thirty Consecutive Business Days MinimumClosingBidPriceFailedToMaintainInPrecedingThirtyConsecutiveBusinessDays	1.00
CY2023Q2	snpx	Number Of Calendar Days Of Grace Period To Attain Minimum Closing Bid Price NumberOfCalendarDaysOfGracePeriodToAttainMinimumClosingBidPrice	180
CY2023Q2	snpx	Stock Priceto Be Maintained For Minimum Of Ten Consecutive Business Days In Grace Period To Achieve Compliance StockPricetoBeMaintainedForMinimumOfTenConsecutiveBusinessDaysInGracePeriodToAchieveCompliance	1.00
CY2023Q2	snpx	Number Of Minimum Consecutive Business Days In Grace Period To Attain Minimum Bid Price Requirement To Achieve Compliance NumberOfMinimumConsecutiveBusinessDaysInGracePeriodToAttainMinimumBidPriceRequirementToAchieveCompliance	10
CY2023Q2	snpx	Number Of Calendar Days Of Grace Period To Attain Minimum Closing Bid Price NumberOfCalendarDaysOfGracePeriodToAttainMinimumClosingBidPrice	180
CY2023Q2	snpx	Stock Priceto Be Maintained For Minimum Of Ten Consecutive Business Days In Grace Period To Achieve Compliance StockPricetoBeMaintainedForMinimumOfTenConsecutiveBusinessDaysInGracePeriodToAchieveCompliance	1.00
CY2023Q2	snpx	Number Of Minimum Consecutive Business Days In Grace Period To Attain Minimum Bid Price Requirement To Achieve Compliance NumberOfMinimumConsecutiveBusinessDaysInGracePeriodToAttainMinimumBidPriceRequirementToAchieveCompliance	10
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28700000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37500000
CY2023Q4	snpx	Cash And Cash Equivalents Expected Amount At Financial Reporting Date CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate	26300000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Use of Estimates:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9114861
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8372426
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	2100000
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	26600000
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	64000
CY2022Q4	snpx	Capitalized Research And Development Services CapitalizedResearchAndDevelopmentServices	0
CY2023Q4	snpx	Capitalized Research And Development Services CapitalizedResearchAndDevelopmentServices	0
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	94800000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26600000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6038504
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5573957
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1268086
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1170531
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-341003
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-717819
CY2023	snpx	Income Tax Reconciliation Change In Fair Value Of Warrants And Derivative Liabilities IncomeTaxReconciliationChangeInFairValueOfWarrantsAndDerivativeLiabilities	-126475
CY2022	snpx	Income Tax Reconciliation Change In Fair Value Of Warrants And Derivative Liabilities IncomeTaxReconciliationChangeInFairValueOfWarrantsAndDerivativeLiabilities	-1765050
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3892572
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4447310
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	6115
CY2023	snpx	Effective Income Tax Rate Reconciliation Return To Provision EffectiveIncomeTaxRateReconciliationReturnToProvision	-2163122
CY2022	snpx	Effective Income Tax Rate Reconciliation Return To Provision EffectiveIncomeTaxRateReconciliationReturnToProvision	-793910
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26635550
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23492415
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1978436
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1838861
CY2022Q4	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	475918
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	16
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1621646
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1487718
CY2023Q4	snpx	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	30235648
CY2022Q4	snpx	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	26343076
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30235648
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26343076
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	0
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	snpx	Number Of Votes Per Share Owned NumberOfVotesPerShareOwned	1
CY2022Q4	snpx	Percentage Of Common Stock Shares Agreed To Register Under November Registration Rights Agreement PercentageOfCommonStockSharesAgreedToRegisterUnderNovemberRegistrationRightsAgreement	2
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3395945
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-700000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1800000
CY2022	snpx	Warrant Issuance Costs WarrantIssuanceCosts	900000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	625000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	625000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4375000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	661850
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.27
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	80000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.87
CY2023	snpx	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	741850
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.15
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	661850
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y6M
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023Q4	us-gaap	Share Price SharePrice	0.272
CY2022Q4	us-gaap	Share Price SharePrice	1.16
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14000000000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y2M26D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1009325
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1776668
CY2022Q1	snpx	Warrants Fair Value Disclosure WarrantsFairValueDisclosure	75000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6265525
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2028762
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	1049368
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	65000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7179919
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7179919
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.79
CY2023	snpx	Warrants And Rights Outstanding Remaining Term WarrantsAndRightsOutstandingRemainingTerm	P2Y8M12D
CY2023Q4	snpx	Intrinsic Value Of Warrants IntrinsicValueOfWarrants	37000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	553150
CY2023	snpx	Number Of Warrant Holders Who Exercised Warrants NumberOfWarrantHoldersWhoExercisedWarrants	0

Files In Submission

Name	View Source	Status
0001410578-24-000410-index-headers.html	Edgar Link	pending
0001410578-24-000410-index.html	Edgar Link	pending
0001410578-24-000410.txt	Edgar Link	pending
0001410578-24-000410-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snpx-20231231.xsd	Edgar Link	pending
snpx-20231231x10k.htm	Edgar Link	pending
snpx-20231231x10k001.jpg	Edgar Link	pending
snpx-20231231x10k004.jpg	Edgar Link	pending
snpx-20231231x10k005.jpg	Edgar Link	pending
snpx-20231231x10k007.jpg	Edgar Link	pending
snpx-20231231xex19d1.htm	Edgar Link	pending
snpx-20231231xex23d1.htm	Edgar Link	pending
snpx-20231231xex31d1.htm	Edgar Link	pending
snpx-20231231xex31d2.htm	Edgar Link	pending
snpx-20231231xex32d1.htm	Edgar Link	pending
snpx-20231231xex97d1.htm	Edgar Link	pending
snpx-20231231_def.xml	Edgar Link	unprocessable
snpx-20231231_lab.xml	Edgar Link	unprocessable
snpx-20231231x10k_htm.xml	Edgar Link	completed
snpx-20231231_cal.xml	Edgar Link	unprocessable
snpx-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNPX
Synaptogenix, Inc. Stock $snpx

2024 Q1 Form 10-K Financial Statement

#000141057824000410 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNPX Synaptogenix, Inc. Stock $snpx

2024 Q1 Form 10-K Financial Statement

#000141057824000410 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNPX
Synaptogenix, Inc. Stock $snpx